FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average be	urden								
- 1	L	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								(,										
1. Name and Address of Reporting Person* BENEVICH ERIC							2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX]								onship of Reporting all applicable) Director Officer (give title		on(s) to Issi 10% Ow Other (s	vner
(Last) (First) (Middle) 12780 EL CAMINO REAL						3. Date of Earliest Transaction (Month/Day/Year) 04/15/2024								^ below		nercial	below)	, ,
(Street) SAN DII	Street) SAN DIEGO CA 92130					If Amer	ndme	nt, Date	of Ori	ginal Fi	iled (Month/Da	Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I -	Non-Deri	ivativ	e Sec	curit	ties A	cquir	ed, D)isposed o	of, or B	eneficial	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye						Execution Dat			3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr.			Securi Benefi Owned	5. Amount of Securities Beneficially Owned Following		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price		ed ction(s) 3 and 4)			(Instr. 4)
Common Stock 04/15/202						.4			M		7,231	A	\$81.49	4	8,009	D		
Common Stock 04/15/202						4			S ⁽¹⁾		7,231	D	\$133.3646	5(2) 4	0,778	D		
Common Stock 04/15/202						4			M		12,587	Α	\$81.05	53,365		D		
Common Stock 04/15/202						4			S ⁽¹⁾		12,587	D	\$133.3646	5(2) 4	0,778	D		
			Гable								sposed of s, converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)			ivative urities uired or oosed O) (Instr.	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amount or Number of Shares					
Non- Qualified Stock Option	\$81.49	04/15/2024			M			7,231		(3)	02/05/2028	Common Stock	7,231	\$81.49	26,292	2	D	
Non- Qualified Stock	\$81.05	04/15/2024			M			12,587		(4)	02/07/2029	Common	12,587	\$81.05	0		D	

Explanation of Responses:

- 1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$131.56 to \$136.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- 3. The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018. These options will expire ten years from the date of grant on February 05, 2028.
- 4. The option was granted February 7, 2019 and vested in 48 equal monthly installments beginning March 7, 2019. These options will expire ten years from the date of grant on February 07, 2029.

Remarks:

Option

/s/ Darin Lippoldt, Attorney-in-04/17/2024 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.